{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:34:09Z","timestamp":1740180849805,"version":"3.37.3"},"reference-count":15,"publisher":"Consilium Medicum","issue":"8","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. Our aim was to give a comparative assessment of the effectiveness of using narlaprevir in combination with pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) and interferon-free mode in patients with chronic hepatitis C (CHC).\r\nMaterials and methods. The prospective cohort study included 187 patients infected with genotype 1b of hepatitis C virus. Of these, 107 (the 1st group of patients) received narlaprevir  200 mg once a day, ritonavir  100 mg once a day, Peg-IFN-alpha-2a  180 mkg subcutaneously once a week and ribavirin at a dose depending on body weight (10001200 mg per day) for 12 weeks, and then the standart \"dual\" therapy (Peg-IFN-alpha-2a + ribavirin) was continued until 24 weeks. Patients of the 2nd group (n=80) received antiviral therapy in an interferon-free mode. They received narlaprevir  200 mg once daily, ritonavir  100 mg once daily, and daclatasvir  60 mg once daily for 12 weeks.\r\nResults. With the use of an interferon-containing treatment regimen, a sustained virological response was achieved in 92.4% of previousle untreated patients with CH and in 66.7% patients with \"unsuccessful\" experience of the previous course of treatment. In 5.6% of cases, there was an early termination of treatment due to the development of adverse events. 80 (100%) patients completed the course of treatment with narlaprevir in the interferon-free mode. Sustained virological response was reached by 75 (90%) patients.\r\nConclusion. Real clinical practice indicates that the use of narlaprevir in the non-interferon mode is not inferior in efficiency to the interferon-containing treatment regimen and demonstrates a more favorable safety profile.<\/jats:p>","DOI":"10.26442\/00403660.2022.08.201774","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T16:45:33Z","timestamp":1665593133000},"page":"979-984","source":"Crossref","is-referenced-by-count":1,"title":["Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C"],"prefix":"10.26442","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-667X","authenticated-orcid":false,"given":"Irina P.","family":"Grushko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-6126","authenticated-orcid":false,"given":"Elena B.","family":"Romanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3912-0291","authenticated-orcid":false,"given":"Tatiana I.","family":"Tverdokhlebova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-2667","authenticated-orcid":false,"given":"Marina N.","family":"Gapon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-4261","authenticated-orcid":false,"given":"Svetlana Y.","family":"Vodyanitskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.24411\/2411-8621-2018-12002"},{"key":"ref2","unstructured":"\u041c\u0430\u0437\u0438\u043d\u0430 \u041d.\u041a., \u041c\u0430\u0437\u0438\u043d \u041f.\u0412. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u043e\u0434\u0445\u043e\u0434\u044b \u043a \u0440\u0435\u0448\u0435\u043d\u0438\u044e \u043f\u0440\u043e\u0431\u043b\u0435\u043c \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0432\u0438\u0440\u0443\u0441\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u0432 (\u043e\u0431\u0437\u043e\u0440). \u0412\u044f\u0442\u0441\u043a\u0438\u0439 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0439 \u0432\u0435\u0441\u0442\u043d\u0438\u043a. 2017;3(55):73-8. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/cyberleninka.ru\/article\/n\/sovremennye-podhody-k-resheniyu-problem-lecheniya-virusnyh-gepatitov. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Mazina NK, Mazin PV. Modern approaches to problems of viral hepatitis treatment (review). Medical Newsletter of Vyatka. 2017;3(55):73-8. Available at: https:\/\/cyberleninka.ru\/article\/n\/sovremennye-podhody-k-resheniyu-problem-lecheniya-virusnyh-gepatitov. Accessed: 24.07.2022 (in Russian)]."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587115-10"},{"key":"ref4","unstructured":"\u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u0430\u044f \u0441\u043b\u0443\u0436\u0431\u0430 \u043f\u043e \u043d\u0430\u0434\u0437\u043e\u0440\u0443 \u0432 \u0441\u0444\u0435\u0440\u0435 \u0437\u0430\u0449\u0438\u0442\u044b \u043f\u0440\u0430\u0432 \u043f\u043e\u0442\u0440\u0435\u0431\u0438\u0442\u0435\u043b\u0435\u0439 \u0438 \u0431\u043b\u0430\u0433\u043e\u043f\u043e\u043b\u0443\u0447\u0438\u044f \u0447\u0435\u043b\u043e\u0432\u0435\u043a\u0430. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/www.rospotrebnadzor.ru\/about\/info\/predpr\/news_predpr.php?ELEMENT_ID=18523&sphrase_id=4220575. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Federal Service for Supervision of Consumer Rights Protection and Human Welfare. Available at: https:\/\/www.rospotrebnadzor.ru\/about\/info\/predpr\/news_predpr.php?ELEMENT_ID=18523&sphrase_id=4220575. Accessed: 24.07.2022 (in Russian)]."},{"key":"ref5","unstructured":"\u0411\u0430\u0446\u043a\u0438\u0445 \u0421.\u041d. \u0411\u0435\u0437\u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d\u043e\u0432\u0430\u044f \u0442\u0435\u0440\u0430\u043f\u0438\u044f \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421: \u0441\u043c\u0435\u043d\u0430 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432 \u0438\u043b\u0438 \u043d\u043e\u0432\u0430\u044f \u043f\u0430\u0440\u0430\u0434\u0438\u0433\u043c\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u044f? \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b \u0433\u0430\u0441\u0442\u0440\u043e\u044d\u043d\u0442\u0435\u0440\u043e\u043b\u043e\u0433\u0438\u0438, \u0433\u0435\u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438, \u043a\u043e\u043b\u043e\u043f\u0440\u043e\u043a\u0442\u043e\u043b\u043e\u0433\u0438\u0438. 2014;24(4):23-31. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: http:\/\/old-gastro-j.ru\/files\/_2014_4_s3_1417779180.pdf. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Batskikh SN. Interferon-free therapy for chronic hepatitis C: drug change or new treatment paradigm? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):23-31. Available at: http:\/\/old-gastro-j.ru\/files\/_2014_4_s3_1417779180.pdf. Accessed: 23.11.2021 (in Russian)]."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.22625\/2072-6732-2017-9-2-101-110"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.22416\/1382-4376-2017-27-6-41-51"},{"key":"ref8","unstructured":"\u0411\u0430\u043a\u0443\u043b\u0438\u043d \u0418.\u0413. \u041d\u0430\u0440\u043b\u0430\u043f\u0440\u0435\u0432\u0438\u0440 \u2013 \u043e\u0442\u0435\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0439 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u043f\u0440\u044f\u043c\u043e\u0433\u043e \u043f\u0440\u043e\u0442\u0438\u0432\u043e\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0433\u043e \u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f \u0434\u043b\u044f \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421. \u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f PIONEER. \u041f\u043e\u043b\u0438\u043a\u043b\u0438\u043d\u0438\u043a\u0430. 2016;5(1):52-4. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/medi.ru\/info\/13342\/ \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Bakulin IG. Narlaprevir \u2013 domestic direct antiviral agent for chronic hepatitis C treatment. PIONEER study results. Poliklinika. 2016;5(1):52\u201354. Available at: https:\/\/medi.ru\/info\/13342\/. Accessed: 24.07.2022 (in Russian)]."},{"key":"ref9","unstructured":"\u0411\u0443\u0440\u043d\u0435\u0432\u0438\u0447 \u042d.\u0417., \u0422\u0438\u0445\u043e\u043d\u043e\u0432\u0430 \u042e.\u041d., \u0429\u0430\u043d\u0438\u0446\u0438\u043d\u0430 \u0421.\u0415. \u041d\u0430\u0440\u043b\u0430\u043f\u0440\u0435\u0432\u0438\u0440, \u0431\u0443\u0441\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u0439 \u0440\u0438\u0442\u043e\u043d\u0430\u0432\u0438\u0440\u043e\u043c, \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0441 \u043f\u0435\u0433\u0438\u043b\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u043c \u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d\u043e\u043c-\u03b1 \u0438 \u0440\u0438\u0431\u0430\u0432\u0438\u0440\u0438\u043d\u043e\u043c \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2014;23(5):34-9. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/medi.ru\/info\/13344\/. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Burnevitch EZ, Tikhonova NYu, Shanitsina SE. Narlaprevir\/ritonavir with peginterferon\/ribavirin in the treatment of chronic hepatitis C. Clinical Pharmacology and Therapy. 2014;23(5):34-9. Available at: https:\/\/medi.ru\/info\/13344\/. Accessed: 24.07.2022 (in Russian)]."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22625\/2072-6732-2017-9-100-103"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23899"},{"key":"ref12","unstructured":"\u0411\u0443\u0440\u043d\u0435\u0432\u0438\u0447 \u042d.\u0417., \u0413\u0443\u0441\u0435\u0432 \u0414.\u0410., \u0417\u043d\u043e\u0439\u043a\u043e \u041e.\u041e., \u0438 \u0434\u0440. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u044c \u043d\u0430\u0440\u043b\u0430\u043f\u0440\u0435\u0432\u0438\u0440\u0430\/\u0440\u0438\u0442\u043e\u043d\u0430\u0432\u0438\u0440\u0430 \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0441 \u0434\u0430\u043a\u043b\u0430\u0442\u0430\u0441\u0432\u0438\u0440\u043e\u043c \u0443 \u0440\u0430\u043d\u0435\u0435 \u043d\u0435 \u043f\u043e\u043b\u0443\u0447\u0430\u0432\u0448\u0438\u0445 \u043f\u0440\u043e\u0442\u0438\u0432\u043e\u0432\u0438\u0440\u0443\u0441\u043d\u0443\u044e \u0442\u0435\u0440\u0430\u043f\u0438\u044e \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u043c \u0421 \u0431\u0435\u0437 \u0446\u0438\u0440\u0440\u043e\u0437\u0430 \u043f\u0435\u0447\u0435\u043d\u0438, \u0438\u043d\u0444\u0438\u0446\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u0445 \u0432\u0438\u0440\u0443\u0441\u043e\u043c \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421 \u0433\u0435\u043d\u043e\u0442\u0438\u043f\u0430 1b. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2018;27(4):35-9. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/clinpharm-journal.ru\/articles\/2018-4\/effektivnost-i-bezopasnost-narlaprevira-ritonavira-v-kombinatsii-s-daklatasvirom-u-ranee-ne-poluchavshih-protivovirusnuyu-terapiyu-bolnyh-hronicheskim-gepatitom-s-bez-tsirroza-pecheni-infitsirovannyh\/ \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 24.07.2022 [Burnevich EZ, Gusev DA, Znoyko OO, et al. Efficacy and safety of narlaprevir\/ritonavir and daclatasvir combination in the treatment naive, noncirrhotic patients with hepatitis C virus genotype 1b. Clinical Pharmacology and Therapy. 2018;27(4):35-9. Available at: https:\/\/clinpharm-journal.ru\/articles\/2018-4\/effektivnost-i-bezopasnost-narlaprevira-ritonavira-v-kombinatsii-s-daklatasvirom-u-ranee-ne-poluchavshih-protivovirusnuyu-terapiyu-bolnyh-hronicheskim-gepatitom-s-bez-tsirroza-pecheni-infitsirovannyh\/. Accessed: 24.07.2022 (in Russian)]."},{"key":"ref13","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2020. Available at: https:\/\/www.easl.eu\/publication\/easl-recommendations-on-treatment-of-hepatitis-c-2020\/. Accessed: 24.07.2022."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.22328\/2077-9828-2016-8-2-77-83"},{"key":"ref15","unstructured":"\u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430\u043c\u0438 \u0412 \u0438 \u0421. \u041f\u043e\u0434 \u0440\u0435\u0434. \u0412.\u0422. \u0418\u0432\u0430\u0448\u043a\u0438\u043d\u0430, \u041d.\u0414 \u042e\u0449\u0443\u043a\u0430. \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2015 [Rekomendatsii po diagnostike i lecheniiu vzroslykh bol'nykh gepatitami B i Ts. Pod red. VT Ivashkina, ND Yushchuka. Moscow: GEOTAR-Media, 2015 (in Russian)]."}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/89578\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/89578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T16:45:42Z","timestamp":1665593142000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/89578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,10,12]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2022.08.201774","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}